WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in the development of sustained release drug delivery products for the treatment of back of the eye disease including the product candidate Iluvien™ for the treatment of Diabetic Macular Edema, today announced that it ranked 15th on the 2010 Deloitte Technology Fast 500™. Deloitte ranked the top 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America based on the percentage of fiscal year revenue growth during the period from 2005-2009.
